Advanced Medical Solutions Group (CHIX:AMSl) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Advanced Medical Solutions Group Forward PE Ratio Related Terms
Advanced Medical Solutions Group Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group Forward PE Ratio Chart
Advanced Medical Solutions Group Annual Data
Trend
2025-12
Forward PE Ratio
15.54
Advanced Medical Solutions Group Semi-Annual Data
2025-06
2025-12
Forward PE Ratio
17.77
15.54
CHIX:AMSL vs ISRG, BDX, MDLN: Forward PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's Forward PE Ratio falls into.
Advanced Medical Solutions Group Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Advanced Medical Solutions Group (CHIX:AMSL) has a Forward PE Ratio of 20.50 as of Jul. 10, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Advanced Medical Solutions Group and its competitors. According to the industry distribution chart, Advanced Medical Solutions Group ranks #218 out of 392 companies in the Medical Devices & Instruments industry, placing it in the top 55.6%.
Is Advanced Medical Solutions Group's Forward PE Ratio too high?
Advanced Medical Solutions Group's current Forward PE Ratio is 20.50. The Medical Devices & Instruments industry median Forward PE Ratio is 19.17. Advanced Medical Solutions Group's value of 20.50 is 6.9% above this industry median. Based on the distribution chart, Advanced Medical Solutions Group ranks #218 out of 392 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Advanced Medical Solutions Group has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's Forward PE Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #218 out of 392 companies for Forward PE Ratio. This places Advanced Medical Solutions Group in the lower half of its industry. The industry median Forward PE Ratio is 19.17. Advanced Medical Solutions Group's value of 20.50 is 6.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.17, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Medical Solutions Group's current Forward PE Ratio of 20.50 is 6.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Advanced Medical Solutions Group and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current Forward PE Ratio is 20.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.70, compared to a current price of £2.79 — trading 24.7% below its estimated fair value. The current Forward PE Ratio is 20.50 and 6.9% above the Medical Devices & Instruments industry median of 19.17. Advanced Medical Solutions Group's overall GF Score™ is 93/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current Forward PE Ratio is 20.50 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.79 is trading 24.7% below its estimated GF Value™ of £3.70.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for CHIX:AMSL:
Forward PE Ratio: 20.50
GF Value™: £3.70 vs. price of £2.79 (24.7% below fair value)
Industry Position: 6.9% above the Medical Devices & Instruments median (#218 of 392)
No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group Business Description
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
93GF Score
Get the complete analysis for CHIX:AMSL
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMSL has been successfully added to your 